An observational study in Inflammatory Bowel Diseases and Irritable Bowel Syndrome, sponsored by Bo-In Lee. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-03.
Sponsored by Bo-In Lee · Observational
The aims of this study is to investigate a blood-based biomarker that can replace endoscopy in patients with inflammatory bowel disease. For this purpose, blood sample of patients wiht inflammatory bowel disease (ulcerative colitis, Crohn 's disease) was collected at the same time the endoscopy is performed, stored after centrifugation, and analyzed accordingly. Selected biomarkers from the blood sample were investigated to compare those of patients with inflammatory bowel disease and those of general controls. Males and females over the age of 19 participated in the study and are excluded if they have chronic kidney disease or blood clotting disease. The outcome is a find of a blood-based biomarker that best reflects a disease activity.
Inflammatory bowel disease refers to chronic inflammation of the unknown origin that occurs in the intestine. It usually refers to ulcerative colitis and Crohn's disease, which are idiopathic inflammatory bowel diseases. While it had been known to be a common disease in the western world, in recent decades the incidence of ulcerative colitis and Crohn's disease has rapidly increased in Korea as well. Endoscopic examination is a gold standard in order to determine the activity of inflammatory bowel disease, but it is hardly performed due to the cost and time of a test. Therefore, it is necessary to find a blood-based biomarker that replaces endoscopy. The objective of the study is to identify a new inflammatory marker that replaces endoscopy by comparing blood samples of patients with inflammatory bowel disease with those of general controls.
963 studies on the registry are indexed under Intestinal Diseases; 174 are open to participants now.
This study's planned enrollment of 200 is above the median of 140 across 377 observational studies indexed under Intestinal Diseases.
Browse Intestinal Diseases studies →Bo-In Lee is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
inflammatory bowel disease (ulcerative colitis, Crohn's Dz.) irritable bowel syndrome normal control
Exclusion Criteria:
inflammatory bowel disease such as Ulcerative colitis and Crohn's disease
Other: inflammatory bowel disease · Other: IBS or Normal Control
irritable bowel syndrome patients normal patients
Other: inflammatory bowel disease · Other: IBS or Normal Control
blood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP
blood based biomarker compared normal control with IBD
measurement of blood-based biomarkers to predict disease activity 1
REG3 alpha (ng/mL)
Time frame: within 12 weeks of the blood sampling
measurement of blood-based biomarkers to predict disease activity 2
hs-CRP (mg/dL)
Time frame: within 12 weeks of the blood sampling
measurement of blood-based biomarkers to predict disease activity 3
serum calprotectin (ng/mL)
Time frame: within 12 weeks of the blood sampling
Age (years)
age at the time of study enrolled
Time frame: at the time of study enrolled
Gender (M/F)
male of female
Time frame: at the time of study enrolled
disease duration (months)
duration of disease
Time frame: at the time of study enrolled
disease onset (years)
age at which the disease begins
Time frame: at the time of study enrolled
Plan to share: No
This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.